Over the last 7 days, the market has remained flat, but over the past 12 months, it has risen by 17%, with earnings forecast to grow annually by 18%. For investors willing to explore beyond well-known stocks, penny stocks—often representing smaller or newer companies—can still offer intriguing opportunities. While the term may seem outdated, these stocks remain relevant for those seeking affordability and growth potential when aligned with strong financial health.

Let's dive into some prime choices out of the screener.

Entera Bio (ENTX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Entera Bio Ltd. is a clinical-stage company focused on developing oral peptides and protein replacement therapies in Israel and internationally, with a market cap of $98.09 million.

Operations: Entera Bio Ltd. has not reported any revenue segments.

Market Cap: $98.09M

Entera Bio Ltd., a clinical-stage biotech company, remains pre-revenue with a market cap of US$98.09 million and no significant revenue streams yet. Although unprofitable and not expected to achieve profitability in the next three years, it has maintained shareholder value without meaningful dilution over the past year. The company's short-term assets significantly exceed its liabilities, providing some financial stability despite having only five months of cash runway based on free cash flow estimates before recent capital raises. Recent developments include positive FDA feedback for its osteoporosis treatment EB613, advancing towards Phase 3 trials with promising preliminary data supporting its efficacy as an oral alternative to injectable therapies.

Vuzix (VUZI)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Vuzix Corporation designs, manufactures, and markets AI-powered smart glasses, waveguides, and augmented reality technologies globally with a market cap of $190.43 million.

Operations: The company generates revenue from its Video Eyewear Products segment, totaling $6.09 million.

Market Cap: $190.43M

Vuzix Corporation, with a market cap of US$190.43 million, is experiencing financial challenges despite its innovative smart glasses and waveguide technologies. The company reported a Q1 2026 revenue of US$1.39 million but remains unprofitable, with losses increasing at an annual rate of 8.9% over the past five years. Vuzix's management and board are seasoned, yet the company faces volatility in share price and has less than a year of cash runway based on current free cash flow trends. Recent events include being dropped from multiple Russell indices and showcasing advanced solutions at industry events like SOF Week 2026, highlighting potential defense applications for its technology amidst insider selling concerns.

MacroGenics (MGNX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing antibody-based therapeutics for cancer treatment in the United States with a market cap of approximately $288.58 million.

Operations: The company generates revenue of $157.08 million from its activities related to the development and commercialization of monoclonal antibody-based therapeutics.

Market Cap: $288.58M

MacroGenics, Inc., with a market cap of US$288.58 million, is navigating the challenges typical of clinical-stage biopharmaceutical companies. Despite being unprofitable, it has reduced losses by 25.5% annually over five years and maintains a cash runway exceeding one year based on current free cash flow. The company recently secured a US$24.5 million milestone payment from Sanofi following FDA approval for TZIELD, enhancing its financial position amidst high share price volatility. MacroGenics was added to several Russell indices in June 2026, reflecting its growing recognition in the investment community despite ongoing operational hurdles.

Key Takeaways

• Gain an insight into the universe of 326 US Penny Stocks by clicking here.
• Seeking Other Investments? AI is about to change healthcare. These 127 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.